{"alternate_names":["Absent corpus callosum cataract immunodeficiency"],"alternate_symbols":[],"id":"2298","medgen_id":"C1855772","name":"Vici syndrome","symbol":"VICIS","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Absent+Corpus+Callosum+Cataract+Immunodeficiency/81\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Absent corpus callosum cataract immunodeficiency\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"vici-syndrome\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"242840\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"242840\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Office of Rare Diseases\",\"id\":\"448\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"1493\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":["CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC, DUE TO DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY","Chondrodysplasia punctata, rhizomelic, due to dihydroxyacetonephosphate","Dihydroxyacetonephosphate acyltransferase deficiency","GLYCERONEPHOSPHATE O-ACYLTRANSFERASE DEFICIENCY","GNPAT DEFICIENCY","Peroxisomal dihydroxyacetonephosphate acyltransferase deficiency"],"alternate_symbols":[],"content":"{\"AttributeSet\":[{\"Attribute\":{\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\",\"$\":\"loss of function\"},\"XRef\":[{\"@ID\":\"GTR000519107\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000030344\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000512382\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000070509\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000318886\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000508587\",\"@DB\":\"Genetic Testing Registry (GTR)\"}]}]}","gard_id":9429,"id":"4353","medgen_id":"C1857242","name":"Rhizomelic chondrodysplasia punctata type 2","symbol":"RCDP2","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Rhizomelic+chondrodysplasia+punctata+type+2/6310\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009112\",\"type\":null,\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"222765\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"222765\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC, DUE TO DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"222765\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"GLYCERONEPHOSPHATE O-ACYLTRANSFERASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"222765\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"GNPAT DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"222765\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"177\",\"type\":null,\"source_field\":null,\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"309796\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":["Cancer predisposition","Neoplastic Syndromes, Hereditary","Tumor predisposition"],"alternate_symbols":[],"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"IARC, 2008\",\"ID\":{\"@Source\":\"pmc\",\"$\":\"3075918\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"ACMG/NSGC, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25394175\"}}],\"AttributeSet\":[{\"Attribute\":{\"@Type\":\"keyword\",\"$\":\"Neoplasm\"}},{\"Attribute\":{\"@Type\":\"keyword\",\"$\":\"Hereditary cancer syndrome\"}}]}","id":"18746","medgen_id":"C0027672","name":"Hereditary cancer-predisposing syndrome","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+Cancer/3345\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Cancer predisposition\"}","{\"db\":\"MeSH\",\"id\":\"D009386\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Neoplastic Syndromes, Hereditary\"}","{\"db\":\"SNOMED CT\",\"id\":\"699346009\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}"]}
{"alternate_names":["Cerebral palsy, spastic quadriplegic, 5","adaptor protein 4 (AP-4) deficiency syndrome"],"alternate_symbols":["CPSQ5"],"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"AAN/CNS, 2004\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"15037681\"}},{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"30543385\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK535153\"}]}]}","id":"16052","medgen_id":"C3279738","name":"Spastic paraplegia 47, autosomal recessive","public_definition":"AP-4-associated hereditary spastic paraplegia (HSP), also known as AP-4 deficiency syndrome, is a group of neurodegenerative disorders characterized by a progressive, complex spastic paraplegia with onset typically in infancy or early childhood. Early-onset hypotonia evolves into progressive lower-extremity spasticity. The majority of children become non-ambulatory and usually wheelchair bound. Over time spasticity progresses to involve the upper extremities, resulting in a spastic tetraplegia. Associated complications include dysphagia, contractures, foot deformities, dysregulation of bladder and bowel function, and a pseudobulbar affect. About 50% of affected individuals have seizures. Postnatal microcephaly (usually in the -2SD to -3SD range) is common. All have developmental delay. Speech development is significantly impaired and many affected individuals remain nonverbal. Intellectual disability in older children is usually moderate to severe.","symbol":"SPG47","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Cerebral+palsy%2C+spastic+quadriplegic%2C+5/7944\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Cerebral palsy, spastic quadriplegic, 5\"}","{\"db\":\"OMIM\",\"id\":\"614066\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"614066\",\"type\":\"MIM\",\"source_field\":\"alternate_symbols\",\"source_detail\":\"CPSQ5\"}","{\"db\":\"OMIM\",\"id\":\"614066\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"280763\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":["FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1","SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT","SPG3","Spastic Paraplegia 3A"],"alternate_symbols":["FSP1"],"content":"{\"Citation\":{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"20862796\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK45978\"}]}}","id":"15930","medgen_id":"C2931355","name":"Spastic paraplegia 3","public_definition":"Spastic paraplegia 3A (SPG3A) is a hereditary spastic paraplegia (HSP) characterized by progressive bilateral and mostly symmetric spasticity and weakness of the legs, diminished vibration sense caused by degeneration of the corticospinal tracts and dorsal columns, and urinary bladder hyperactivity. The average age of onset is four years. More than 80% of reported individuals manifest spastic gait before the end of the first decade of life. Most persons with early-onset SPG3A have a \"pure\" (\"uncomplicated\") HSP; however, complicated HSP with axonal motor neuropathy and/or distal amyotrophy with lower motor neuron involvement (Silver syndrome phenotype) have been observed. The rate of progression in SPG3A is slow, and wheelchair dependency or need for a walking aid (cane, walker, or wheelchair) is relatively rare.","symbol":"SPG3A","type":"Disease","xrefs":["{\"db\":\"GeneReviews\",\"id\":\"NBK45978\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Spastic Paraplegia 3A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+3/6693\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPG3\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":\"alternate_symbols\",\"source_detail\":\"FSP1\"}","{\"db\":\"OMIM\",\"id\":\"182600\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"606439.0001\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0002\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0003\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0004\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0005\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0006\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0007\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0008\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0009\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0013\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"606439.0014\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5041\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5041\",\"type\":null,\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"100984\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":["HFE-Associated Hereditary Hemochromatosis"],"alternate_symbols":["HFE-HH"],"content":"{\"Citation\":[{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"20301613\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK1440\"}]},{\"@Type\":\"Translational/Evidence-based\",\"@Abbrev\":\"EuroGenetest, 2010\",\"ID\":{\"@Source\":\"pmc\",\"$\":\"2987432\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"USPSTF, 2006\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"16880462\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"AASLD, 2011\",\"ID\":{\"@Source\":\"pmc\",\"$\":\"3149125\"}}],\"AttributeSet\":[{\"Attribute\":{\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\",\"$\":\"loss of function\"},\"XRef\":[{\"@ID\":\"GTR000260619\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000264968\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000332464\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000500638\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000508786\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000028914\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000558915\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000271417\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000500300\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000501267\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000531271\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000551894\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000558542\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000560323\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000521586\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000528695\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000501371\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000507663\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000508970\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000509340\",\"@DB\":\"Genetic Testing Registry (GTR)\"},{\"@ID\":\"GTR000560567\",\"@DB\":\"Genetic Testing Registry (GTR)\"}]}]}","id":"9582","medgen_id":"C3469186","name":"Hemochromatosis type 1","public_definition":"HFE hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of HFE hemochromatosis includes: Persons with clinical HFE hemochromatosis, in whom manifestations of end-organ damage secondary to iron overload are present; Individuals with biochemical HFE hemochromatosis, in whom transferrin-iron saturation is increased and the only evidence of iron overload is increased serum ferritin concentration; and Non-expressing p.Cys282Tyr homozygotes, in whom neither clinical manifestations of HFE hemochromatosis nor iron overload are present. Clinical HFE hemochromatosis is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and anterior pituitary gland. In untreated individuals, early symptoms include: abdominal pain, weakness, lethargy, weight loss, arthralgias, diabetes mellitus; and increased risk of cirrhosis when the serum ferritin is higher than 1,000 ng/mL. Other findings may include progressive increase in skin pigmentation, congestive heart failure, and/or arrhythmias, arthritis, and hypogonadism. Clinical HFE hemochromatosis is more common in men than women.","symbol":"HFE1","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"465508\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":["MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7","NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO","PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO"],"alternate_symbols":[],"content":"{\"AttributeSet\":[{\"Attribute\":{\"@Type\":\"keyword\",\"$\":\"NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO\"},\"XRef\":[{\"@Type\":\"MIM\",\"@ID\":\"612635\",\"@DB\":\"OMIM\"},{\"@ID\":\"603933\",\"@DB\":\"OMIM\"}]}]}","id":"5535","medgen_id":"C2673520","name":"Microvascular complications of diabetes 7","symbol":"MVCD7","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Microvascular+complications+of+diabetes+7/8892\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"603933\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"603933\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612635\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"612635\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7\"}","{\"db\":\"OMIM\",\"id\":\"612635\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612635\",\"type\":\"MIM\",\"source_field\":\"alternate_names\",\"source_detail\":\"PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612635\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"613609.0001\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7\"}","{\"db\":\"OMIM\",\"id\":\"613609.0002\",\"type\":\"Allelic variant\",\"source_field\":\"alternate_names\",\"source_detail\":\"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7\"}"]}
{"alternate_names":["Photosensitive skin","Photosensitive skin rashes","Photosensitivity","Sensitivity to sunlight","Skin photosensitivity","Sun sensitivity"],"alternate_symbols":[],"id":"22083","medgen_id":"C0349506","name":"Cutaneous photosensitivity","type":"Finding","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Photosensitive skin\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Photosensitive skin rashes\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Photosensitivity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Sensitivity to sunlight\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Skin photosensitivity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"alternate_names\",\"source_detail\":\"Sun sensitivity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000992\",\"type\":\"primary\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005594\",\"type\":\"secondary\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006831\",\"type\":\"secondary\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007538\",\"type\":\"secondary\",\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":["HH"],"content":"{\"Citation\":[{\"@Type\":\"review\",\"@Abbrev\":\"GeneReviews\",\"ID\":[{\"@Source\":\"PubMed\",\"$\":\"20301613\"},{\"@Source\":\"BookShelf\",\"$\":\"NBK1440\"}]},{\"@Type\":\"Translational/Evidence-based\",\"@Abbrev\":\"EuroGenetest, 2010\",\"ID\":{\"@Source\":\"pmc\",\"$\":\"2987432\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"USPSTF, 2006\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"16880462\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"AASLD, 2011\",\"ID\":{\"@Source\":\"pmc\",\"$\":\"3149125\"}}]}","id":"33108","medgen_id":"C0392514","name":"Hereditary hemochromatosis","public_definition":"HFE hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of HFE hemochromatosis includes: Persons with clinical HFE hemochromatosis, in whom manifestations of end-organ damage secondary to iron overload are present; Individuals with biochemical HFE hemochromatosis, in whom transferrin-iron saturation is increased and the only evidence of iron overload is increased serum ferritin concentration; and Non-expressing p.Cys282Tyr homozygotes, in whom neither clinical manifestations of HFE hemochromatosis nor iron overload are present. Clinical HFE hemochromatosis is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and anterior pituitary gland. In untreated individuals, early symptoms include: abdominal pain, weakness, lethargy, weight loss, arthralgias, diabetes mellitus; and increased risk of cirrhosis when the serum ferritin is higher than 1,000 ng/mL. Other findings may include progressive increase in skin pigmentation, congestive heart failure, and/or arrhythmias, arthritis, and hypogonadism. Clinical HFE hemochromatosis is more common in men than women.","symbol":"HFE","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+hemochromatosis/8521\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\",\"source_field\":\"alternate_symbols\",\"source_detail\":\"HH\"}","{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"PS235200\",\"type\":\"Phenotypic series\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"SNOMED CT\",\"id\":\"35400008\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":[],"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Langer et al., 2012\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"22947299\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"SACHDNC, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23037933\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EASAC/FEAM, 201\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23169492\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NYMAC, 2014\",\"URL\":{\"$\":\"http://www.wadsworth.org/sites/default/files/WebDoc/68970143/DX_Guidelines_2014-10-01.pdf\"},\"CitationText\":{\"$\":\"Diagnostic Guidelines for Confirmation of Screen-Positive Newborn Screening Results\"}},{\"@Type\":\"Recommendation\",\"@Abbrev\":\"ACOG, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25560141\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ESHG/P3G/HUGO/PHGF, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25626707\"}},{\"@Type\":\"general\",\"@Abbrev\":\"Alpha-1 Foundation, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24121147\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"NBSTRN, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24394680\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"EUNENBS, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23652378\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"NSGC, 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23881473\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG/ACOG/NSGC/PQF/SMFM, 2015\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"25730230\"}},{\"@Type\":\"practice guideline\",\"@Abbrev\":\"Skirton et al., 2014\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"24022298\"}},{\"@Type\":\"Position Statement\",\"@Abbrev\":\"ACMG, 2013\",\"ID\":{\"@Source\":\"PubMed\",\"$\":\"23619275\"}}]}","id":"32761","medgen_id":"C0950123","name":"Inborn genetic diseases","type":"Disease","xrefs":["{\"db\":\"MeSH\",\"id\":\"D030342\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":[],"id":"16195","medgen_id":"CN205842","name":"Hemochromatosis type 2","symbol":"HFE2","type":"Disease","xrefs":["{\"db\":\"OMIM\",\"id\":\"602390\",\"type\":null,\"source_field\":\"symbol\",\"source_detail\":null}","{\"db\":\"Orphanet\",\"id\":\"79230\",\"type\":null,\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":[],"id":"17556","medgen_id":"CN517202","name":"not provided","public_definition":"The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.","type":"Disease","xrefs":["{\"db\":\"Developmental Genetics Unit,King Faisal Specialist Hospital & Research Centre\",\"id\":\"13DG0619\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":[],"id":"18728","name":"See cases","type":"PhenotypeInstruction","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"28417","medgen_id":"C0151861","name":"Porphyrinuria","type":"Finding","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010473\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010473\",\"type\":\"primary\",\"source_field\":null,\"source_detail\":null}"]}
{"alternate_names":[],"alternate_symbols":[],"id":"43188","type":"Disease","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"9583","name":"Porphyria cutanea tarda, susceptibility to","type":"Disease","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"9584","name":"Porphyria variegata, susceptibility to","type":"Disease","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"9585","medgen_id":"C3150862","name":"Hemochromatosis, juvenile, digenic","type":"Disease","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"9586","name":"Alzheimer disease, susceptibility to","type":"Disease","xrefs":[]}
{"alternate_names":[],"alternate_symbols":[],"id":"9587","medgen_id":"C3280096","name":"Transferrin serum level quantitative trait locus 2","symbol":"TFQTL2","type":"Disease","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Transferrin+serum+level+quantitative+trait+locus+2/9417\",\"type\":null,\"source_field\":\"name\",\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"614193\",\"type\":\"MIM\",\"source_field\":null,\"source_detail\":null}","{\"db\":\"OMIM\",\"id\":\"614193\",\"type\":\"MIM\",\"source_field\":\"symbol\",\"source_detail\":null}"]}
